期刊
JOURNAL OF CELLULAR PHYSIOLOGY
卷 234, 期 4, 页码 4267-4276出版社
WILEY
DOI: 10.1002/jcp.27195
关键词
asiaticoside; NF-kappa B; NFAT pathway; osteoclast; RANKL
资金
- Guangdong Medical Science and Technology Research Foundation [A2016580]
- Australian Health and Medical Research Council [APP1127396, APP1107828, APP1127156]
- National Natural Science Foundation of China [81573996, 81473697]
Identification of natural compounds that inhibit osteoclastogenesis will facilitate the development of antiresorptive treatment of osteolytic bone diseases. Asiaticoside is a triterpenoid derivative isolated from Centella asiatica, which exhibits varying biological effects like angiogenesis, anti-inflammation, wound healing, and osteogenic differentiation. However, its role in osteoclastogenesis remains unknown. Here, we show that Asiaticoside can suppress RANKL-induced osteoclast formation and bone resorption in a dose-dependent manner. Asiaticoside attenuated the expression of osteoclast marker genes including Ctsk, Atp6v0d2, Nfatc1, Acp5, and Dc-stamp. Furthermore, Asiaticoside inhibited RANKL-mediated NF-B and NFATc1 activities, and RANKL-induced calcium oscillation. Collectively, this study demonstrates that Asiaticoside inhibited osteoclast formation and function through attenuating RANKL-induced key signaling pathways, which may indicate that Asiaticoside is a potential antiresorptive agent against osteoclast-related osteolytic bone diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据